Drug Profile

NI 0801

Alternative Names: Alpha-IP-10; EB 06; NI-0801; α-IP-10

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NovImmune SA
Developer Edesa Biotech; NovImmune SA
Class Antiallergics; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Chemokine CXCL10 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Acute lung injury; Adult respiratory distress syndrome; Vitiligo
Discontinued Allergic contact dermatitis; Primary biliary cirrhosis

Most Recent Events

13 Dec 2024 Edesa Biotech plans to file an IND application with the US FDA for Vitiligo in USA
13 Dec 2024 Edesa Biotech plans a phase II trial for Vitiligo in USA (IV)
10 Jul 2023 Phase-II clinical trials in Vitiligo in Canada (IV) (Light Chain Bioscience pipeline, July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com